Amgen’s Roger Perlmutter joins Heptares

pharmafile | October 23, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Heptares, Roger Perlmutter 

GPCR drug discovery firm Heptares Therapeutics has elected Dr Roger Perlmutter, the former executive VP, Research and Development, at Amgen to its Board of directors as a non-executive director.

Perlmutter was at Amgen from 2001 until his retirement earlier this year. Before this, he was the executive VP of Worldwide Basic Research and Pre-clinical Development at Merck, which he joined in 1997 from the University of Washington, Seattle, where he was Professor and founding chairman of the Department of Immunology.

John Berriman, Heptares’ chairman, said: “Heptares has made enormous progress in recent years, developing its GPCR-focused drug discovery platform and gaining industry validation through several high value deals. We are delighted to welcome Roger to our Board and look forward to benefiting from his extensive US, big biotech and big pharma experience as Heptares advances its pipeline into clinical development.”

Perlmutter added: “Heptares has pioneered structure determination in GPCRs, and has used this information to develop leading therapeutic candidates in metabolic and neuropsychiatric disease.  I am eager to help Malcolm Weir and his team translate these impressive assets into novel therapeutics that will make a difference for patients around the world.”

Related Content

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

Amgen flag

Amgen stomach cancer drug awarded Breakthrough Therapy Designation

Amgen’s investigational therapy, bemarituzumab, for certain types of stomach and esophagus cancer, has been granted …


Amgen to acquire Five Prime Therapeutics for approximately $1.9bn

Amgen has announced it will acquire Five Prime Therapeutics for $38.00 per share in cash, …

Latest content